CRIS Current Research Information System

RAVAIOLI, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.638
EU - Europa 2.777
AS - Asia 1.574
AF - Africa 207
SA - Sud America 14
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.214
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.621
IT - Italia 786
SG - Singapore 587
GB - Regno Unito 550
CN - Cina 549
SE - Svezia 412
DE - Germania 352
IN - India 171
IE - Irlanda 166
VN - Vietnam 140
RU - Federazione Russa 86
BG - Bulgaria 71
CI - Costa d'Avorio 60
TG - Togo 56
FR - Francia 55
UA - Ucraina 50
CH - Svizzera 49
FI - Finlandia 44
ZA - Sudafrica 41
NG - Nigeria 38
EE - Estonia 34
ID - Indonesia 28
JO - Giordania 27
NL - Olanda 25
BE - Belgio 21
AT - Austria 18
CA - Canada 16
PK - Pakistan 16
ES - Italia 12
JP - Giappone 11
HR - Croazia 10
IR - Iran 10
GR - Grecia 9
HK - Hong Kong 9
SC - Seychelles 9
PE - Perù 5
RS - Serbia 5
BR - Brasile 4
KR - Corea 4
TR - Turchia 4
AL - Albania 3
BA - Bosnia-Erzegovina 3
BD - Bangladesh 3
CL - Cile 3
IQ - Iraq 3
MK - Macedonia 3
PH - Filippine 3
PL - Polonia 3
PT - Portogallo 3
TH - Thailandia 3
AU - Australia 2
CZ - Repubblica Ceca 2
EG - Egitto 2
LB - Libano 2
LT - Lituania 2
RO - Romania 2
SA - Arabia Saudita 2
AR - Argentina 1
EC - Ecuador 1
EU - Europa 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MX - Messico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
UG - Uganda 1
Totale 9.214
Salva come PNG Salva come JPEG
Città #
Fairfield 781
Singapore 522
Southend 503
Chandler 415
Ashburn 365
Seattle 220
Woodbridge 217
Santa Clara 212
Bologna 206
Wilmington 182
Houston 178
Cambridge 172
Boardman 169
Dublin 166
Princeton 156
Ann Arbor 125
New York 103
Sofia 69
Dong Ket 62
Abidjan 60
Lomé 56
Milan 51
Nanjing 46
Redmond 46
Westminster 43
Turin 41
Berlin 40
Bremen 39
Abeokuta 38
San Diego 36
Beijing 35
Bern 35
Helsinki 34
Florence 33
Medford 30
Des Moines 29
Redwood City 29
Guangzhou 28
Amman 27
Rome 27
Boydton 26
Jakarta 26
Dearborn 25
Brussels 21
Jinan 21
Washington 19
Padova 18
Saint Petersburg 18
Shanghai 17
Los Angeles 15
Falls Church 14
Nanchang 13
Shenyang 13
Jiaxing 12
Vienna 12
London 11
Changsha 10
Frankfurt am Main 10
Hebei 10
Tianjin 10
Bari 9
Lappeenranta 9
Mahé 9
Shenzhen 9
Wuhan 9
Cesena 8
Kyiv 8
Moscow 8
Ottawa 8
Zhengzhou 8
Amsterdam 7
Chengdu 7
Forlì 7
Hangzhou 7
Hong Kong 7
Lübeck 7
Napoli 7
San Francisco 7
Venice 7
Bühl 6
Chicago 6
Frankfurt Am Main 6
Fuzhou 6
Islamabad 6
Lahore 6
Leawood 6
Madrid 6
Modena 6
Mountain View 6
Naples 6
Ningbo 6
Norwalk 6
Phoenix 6
Ravenna 6
Reggio Emilia 6
Rimini 6
Toronto 6
Buffalo 5
Casalecchio di Reno 5
Falkenstein 5
Totale 6.218
Salva come PNG Salva come JPEG
Nome #
Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study 211
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 187
Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation 184
Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments 155
DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods 151
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 149
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 146
“Are the Expanded Baveno VI Criteria really safe to screen compensated cirrhotic patients for high-risk varices?” 146
Monofocal hepatocellular carcinoma: How much does size matter? 140
Clinical impact of sarcopenia assessment in patients with liver cirrhosis 140
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 138
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 133
A SPLEEN STIFFNESS MEASUREMENT-BASED MODEL FOR THE RECOGNITION OF HIGH RISK VARICES: BAVENO VI CRITERIA AND BEYOND 131
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 130
Gut Microbiota and Celiac Disease 127
IL28 polymorphism and HCC after DAAs for chronic hepatitis C 127
Point shear wave ultrasound elastography with Esaote compared to real-time 2D shear wave elastography with supersonic imagine for the quantification of liver stiffness 125
DAAs treatment in hepatitis C virus recurrence after Liver Transplantation: clinical usefulness of non-invasive methods 124
Pancreatic ultrasound elastography and its clinical use in predicting the risk of pancreatic fistulas after pancreatic resection 124
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 124
Usefulness of liver stiffness measurement in predicting hepatic veno-occlusive disease development in patients who undergo HSCT 121
Corrigendum to “Differences in liver stiffness values obtained with new ultrasound elastography machines and fibroscan: A comparative study” [Dig. Liver Dis. 49 (2017) 802–808](S1590865817302463)(10.1016/j.dld.2017.03.001) 121
Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients 120
A spleen stiffness measurement-based model for the recognition of high risk varices: Baveno VI criteria and beyond 119
Non-invasive measurement of HVPG using graph analysis based on dynamic contrast-enhanced ultrasound with ESAOTE MyLab: The CLEVER Study. 119
Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review 116
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients 115
null 115
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients 114
Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients 114
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 112
Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens 111
P.09.6 IL28 POLYMORPHISM AND HCC DEVELOPMENT AFTER DAAS FOR CHRONIC HEPATITIS C 108
Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update 108
Pattern of macrovascular invasion in hepatocellular carcinoma 108
Liver and Spleen Stiffness Measurements for Assessment of Portal Hypertension Severity in Patients with Budd Chiari Syndrome 107
Non-invasive tests for the prediction of post-hepatectomy liver failure in the elderly 107
Interleukin 28 polymorphisms and hepatocellular carcinoma development after direct acting antiviral therapy for chronihepatitis c 105
THU-490 - Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens 99
The role of Spleen Stiffness measurement as predictor of HCC recurrence after curative resection in cirrhotic patients 98
A spleen stiffness measurement-based model for recognition of high risk varices: Baveno VI criteria and beyond 97
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 97
THU-492 - Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients 96
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 96
Comparison of prognostic models in predicting survival of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: a multicenter cohort study 95
Malnutrition and nutritional therapy in patients with SARS-CoV-2 disease 94
Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection 93
Spleen stiffness by ultrasound elastography 92
Predictive factors for hepatocellular carcinoma recurrence after curative treatments 90
Spleen stiffness measurement predicts the development of primary hepatocellular carcinoma better than hepatic venous pressure gradient 89
A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma 88
Longitudinal evaluation of liver stiffness in three pediatric patients with veno-occlusive disease 86
How to clarify the Baveno VI criteria for ruling out varices needing treatment by noninvasive tests 85
Editorial: collagen proportionate area as a prognostic indicator in NAFLD 85
Prediction of posthepatectomy liver failure: Role of SSM and LSPS 84
Non-invasive tests for the prediction of primary hepatocellular carcinoma 84
null 83
Is Ultrasound Elastography Useful in Predicting Clinically Relevant Pancreatic Fistula After Pancreatic Resection?: A Systematic Review and Meta-analysis 83
Liver stiffness predicts the development of portal hypertension related complications in advanced chronic liver disease 80
Indocyanine green retention test predict the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients 79
Gut microbiota signatures and clinical manifestations in celiac disease children at onset: a pilot study 78
HEPATIC DECOMPENSATION RISK IS REDUCED, BUT NOT ELIMINATED AFTER DIRECT-ACTING ANTIVIRALS: THE ROLE OF SPLEEN STIFFNESS MEASUREMENT 78
THU-086 - The role of spleen stiffness measurement as predictor of hepatocellular carcinoma recurrence after curative resection in cirrhotic patients 76
Encefalopatia epatica 76
Clinical presentation of celiac disease and diagnosis accuracy in a single-center european pediatric cohort over 10 years 76
Sound Conclusions: How Splenic Elastography May Decrease the Need for Endoscopic Variceal Surveillance 75
Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation after Direct-Acting Antivirals in HCV Cirrhotic Patients 72
Pancreatic ultrasound elastography is not useful to predict the risk of pancreatic fistulas after pancreatic resection 70
A combined Baveno VII and spleen stiffness algorithm to improve the non-invasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease 69
Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients 68
Nutrition in patients with type 2 diabetes: Present knowledge and remaining challenges 68
Antibiotic prophylaxis in patients with cirrhosis: Current evidence for clinical practice 64
Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis 63
Ruolo e significato clinico dei metodi non invasivi nella valutazione dell’ipertensione portale nel paziente affetto da epatopatia cronica 60
The role of liver and spleen elastography in advanced chronic liver disease 60
Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis 60
The changing scenario of hepatocellular carcinoma in Italy: an update 59
Real-world prevalence of metabolic associated fatty liver disease (MAFLD) and fibrotic-non-alcoholic steatohepatitis (NASH) in patients with obesity (PwO) in an outpatient specialist clinic in Italy 56
Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness 56
Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients 53
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 51
Transient Elastography Anticipates the Diagnosis of VOD/SOS after Adult Allogeneic Stem Cell Transplant: Results from a Prospective Study 51
Creatine Supplementation to Improve Sarcopenia in Chronic Liver Disease: Facts and Perspectives 48
Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis 42
Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study 42
Determinants of weight, psychological status, food contemplation and lifestyle changes in patients with obesity during the COVID-19 lockdown: a nationwide survey using multiple correspondence analysis 41
A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease 41
The interplay between sarcopenia and portal hypertension predicts ascites and mortality in cirrhosis: Sarcopenia predicts ascites and death in cirrhotic patients 40
Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival 35
Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients 35
Real-life prevalence of Metabolic Associated Fatty Liver Disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a tertiary obesity clinic in Italy 35
Comparison of screening strategies with two new tests to score and diagnose varices needing treatment 34
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation 34
Sarcopenia Predicts Major Complications after Resection for Primary Hepatocellular Carcinoma in Compensated Cirrhosis 34
Metformin and the Liver: Unlocking the Full Therapeutic Potential 33
Sarcopenia predict complications after hepatic resection for primary hepatocellular carcinoma (HCC) in patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH) 32
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 32
Sarcopenia predicts ascitic decompensation and mortality independently of portal hypertension status in patients with advanced chronic liver disease outside the liver transplantation setting 32
Non-invasive diagnosis of clinically significant portal hypertension and treatment with non-selective beta-blockers: a new paradigm 31
Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk 31
Totale 8.996
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.175
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.175
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020728 0 0 0 0 0 0 190 191 178 73 45 51
2020/20211.045 124 53 32 81 90 30 61 91 128 74 40 241
2021/20222.004 59 43 61 85 173 81 60 109 128 112 836 257
2022/20232.046 157 227 91 263 150 174 84 80 391 71 214 144
2023/2024967 62 135 72 76 92 244 33 66 53 66 37 31
2024/20251.758 135 421 367 246 412 169 8 0 0 0 0 0
Totale 9.557